Literature DB >> 21346749

Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.

M Pfister1, J M Whaley, L Zhang, J F List.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21346749     DOI： 10.1038/clpt.2011.16

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  7 in total

1.  Chances and risks of SGLT2 inhibitors.

Authors:  Peter Mayer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-24       Impact factor: 3.000

2.  Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy.

Authors:  Kento Kitada; Daisuke Nakano; Hiroyuki Ohsaki; Hirofumi Hitomi; Tohru Minamino; Junichi Yatabe; Robin A Felder; Hirohito Mori; Tsutomu Masaki; Hiroyuki Kobori; Akira Nishiyama
Journal:  J Diabetes Complications       Date:  2014-06-04       Impact factor: 2.852

3.  Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.

Authors:  Mark C Petrie; Subodh Verma; Kieran F Docherty; Silvio E Inzucchi; Inder Anand; Jan Belohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andre Dukát; Junbo Ge; Jonathan Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Pham Nguyen Vinh; Morten Schou; Sergey Tereshchenko; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; Per Johanson; Peter J Greasley; David Boulton; Olof Bengtsson; Pardeep S Jhund; John J V McMurray
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

Review 4.  Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.

Authors:  Eva M Vivian
Journal:  Drugs Context       Date:  2014-12-19

5.  Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans.

Authors:  Yasong Lu; Steven C Griffen; David W Boulton; Tarek A Leil
Journal:  Front Pharmacol       Date:  2014-12-10       Impact factor: 5.810

6.  SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.

Authors:  Dario Giugliano; Miriam Longo; Lorenzo Scappaticcio; Giuseppe Bellastella; Maria Ida Maiorino; Katherine Esposito
Journal:  Cardiovasc Diabetol       Date:  2021-12-16       Impact factor: 9.951

7.  Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia.

Authors:  Emre Durcan; Serbay Ozkan; Halil Ibrahim Saygi; Mevlut Tamer Dincer; Ozge Polat Korkmaz; Serdar Sahin; Cebrail Karaca; Cem Sulu; Alev Bakir; Hande Mefkure Ozkaya; Sinan Trabulus; Elif Guzel; Nurhan Seyahi; Mustafa Sait Gonen
Journal:  J Diabetes       Date:  2022-02-28       Impact factor: 4.530
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.